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Abstract: Water from wastewater treatment plants contains concentrations of pharmaceutically active
compounds as high as micrograms per liter, which can adversely affect fish health and behavior,
and contaminate the food chain. Here, we tested the ability of the common carp hepatic S9 fraction to
produce the main metabolites from citalopram, metoprolol, sertraline, and venlafaxine. Metabolism
in fish S9 fractions was compared to that in sheep. The metabolism of citalopram was further studied
in fish. Our results suggest a large difference in the rate of metabolites formation between fish
and sheep. Fish hepatic S9 fractions do not show an ability to form metabolites from venlafaxine,
which was also the case for sheep. Citalopram, metoprolol, and sertraline were metabolized by both
fish and sheep S9. Citalopram showed concentration-dependent N-desmethylcitalopram formation
with Vmax = 1781 pmol/min/mg and Km = 29.7 µM. The presence of ellipticine, a specific CYP1A
inhibitor, in the incubations reduced the formation of N-desmethylcitalopram by 30–100% depending
on the applied concentration. These findings suggest that CYP1A is the major enzyme contributing
to the formation of N-desmethylcitalopram. In summary, the results from the present in vitro study
suggest that common carp can form the major metabolites of citalopram, metoprolol, and sertraline.
Keywords: cytochrome P450; metabolite formation; citalopram; sertraline; venlafaxine; metoprolol;
environmental toxicology
1. Introduction
The contamination of aquatic systems by human pharmaceuticals and personal care products is
increasingly concerning. The use of pharmaceuticals is often essential in supporting public health,
treating and curing diseases, and easing symptoms. However, once pharmaceuticals have been absorbed
by the host organism and excreted as the parent compound, their metabolites, or both, can be transferred
into wastewater treatment plant (WWTP) facilities. Currently, such facilities do not have additional
steps to remove pharmaceutically active compounds. Therefore, WWTPs are recognized as hot spots
for releasing pharmaceuticals into aquatic environments [1,2]. These compounds are considered as
pseudo-persistent compounds in WWTP effluents due to regular prescription and continuous use. This
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contributes to chronic exposure of aquatic organisms, such as fish, to human pharmaceuticals. Even
though surface water concentrations typically contain pharmaceutical compounds in the nanogram
to microgram per litter range [3,4], chronic exposure will likely cause adverse effects on non-target
organisms [5–7]. The accumulation of pharmaceutical compounds in the environment can indirectly
affect public health through the food chain [8,9]. The south region of the Czech Republic continues to
farm common carps by traditional methods in ponds. Some of these ponds are connected through a
cascade system with a WWTP outlet. Thus, the WWTP of Vodnˇany town (~7000 inhabitants) discharges
treated water directly into the pond, where common juvenile carps are restocked. Environmental risk
assessments for this pond system have shown that the presence of pharmaceuticals and their metabolites
affected hepatic and intestinal CYP enzymes, fatty acid metabolism, and intestinal microbiome in
common carp [10,11].
WWTPs can act as a channel by which many human 44 pharmaceuticals are further released
into the environment through effluent discharges [12]. Human pharmaceuticals and their metabolites
have been detected in WWTP influent and effluent [13,14]. During the treatment processes at the
WWTP, some of pharmaceuticals are completely removed, and some only partly removed, with the
formation of transformation product. These transformation products might present a risk for ecosystem
contamination [15].
Fish is a good indicator of the presence of pharmaceuticals in water, based on their low capacity
to metabolize and then eliminate them [16]. However, under well-controlled experimental conditions,
when fish are kept in water tanks, and pure pharmaceuticals (e.g., diltiazem) are applied to water for
research purposes, the presence of metabolites after a certain time was also detected in water [17,18].
Therefore, in in situ tests in cascade ponds in Vodnˇany town, citalopram, metoprolol, sertraline,
venlafaxine, and their metabolites have been detected in common carp fish hepatic tissue, water,
and soil [19,20]. It is uncertain whether the metabolites, which have been previously detected in the
pond, are at least partly produced during hepatic metabolism in fish and excreted back to the water.
The discharge scenario of pharmaceuticals release from the WWTP of Vodnˇany town into the pond
system is typical of many European countries, and thus, understanding the ability of fish to metabolize
these compounds is highly relevant [21].
The pharmaceuticals exert their effects by binding to specific proteins and receptors [22].
Similar to mammalians, the piscine cytochrome P450 (CYP) system is the major enzyme in xenobiotic
metabolism [23]. Metabolic pathways of some xenobiotics were characterized using piscine in vitro
models [24,25]. In vitro metabolism of pharmaceutical compounds is commonly studied in liver
microsomes because they contain a high amount of CYPs, flavin-containing monooxygenases,
and uridine glucuronide transferase. The use of S9 fractions, which contain both phases I and
II enzymes, allows investigation of the entire metabolic fate of compounds in conditions that more
closely resemble the physiological condition than when using microsomes [26].
Amino acid sequence of ovine CYP1A1 shows high identity homology of CYP1A1 with other often
used mammalian models like rat (82%, [27]), and pig (>80%, [28]) and even with marine mammals
including minke whale (88%, [28]).
Here we aimed to characterize the formation of the main metabolites of four commonly occurred
pharmaceuticals, and determine if the CYP1A1 isoform is involved in their metabolism using common
carp liver S9 fractions. The study was focused on pharmaceuticals and their main metabolites
previously found in fish from Cezarka pond, which are affected by treated wastewater.
2. Results
Given that, in this study, fish were taken from pond, which receives water from the river, fish hepatic
tissue were characterized with respect to the presence of 72 pharmaceuticals and 6 metabolites, whose
presence is suspected in pond water. The concentrations of all pharmaceuticals in liver tissue were
negligible and confounding factor can be excluded (Supplementary material 1).
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2.1. Characterization of Piscine and Ovine S9 Fraction
Common carp S9 fraction was initially characterized on activity of phase I enzymes, by using of
known substrates, for CYP1A1 and CYP3A-like activity (Table 1). As an additional confirmation of S9
activity, formation of the tris(n-butyl) phosphate (TNBP) metabolite was observed (data not showed).
The metabolite formation was not observed in the incubations without S9 fraction or without substrate.
Table 1. Common carp hepatic S9 characterization biomarkers. Data are present as least squares mean
± SE, n = 12.
Biomarker Units Fish
EROD pmol/min/mg 5.33 ± 1.99
BFCOD pmol/min/mg 5.55 ± 3.58
TNBP +
EROD—ethoxyresorufin O-dealkylation; BFCOD—7-benzyloxy-4-(trifluoromethyl) coumarin O-debenzyloxylase;
TNBP—tris(n-butyl) phosphate; “+”—indicator of tri-iso-butyl phosphate metabolite production from TNBP.
2.2. Metabolites Formation
The formation of the main metabolite of four pharmaceuticals was investigated in the hepatic
S9 fraction of sheep, common carps, and carps injected with 50 mg/kg with BNF to induce CYP1A1
activity. The metabolite formation was observed in optimized conditions.
The formation of metabolites was observed in incubations with citalopram, metoprolol, and
sertraline after 60 min incubation with piscine not induced and induced S9 fractions (Table 2).
In addition to those three compounds, the sheep S9 fraction produced the O-desmethylvenlafaxine
metabolite. The N-desmethylcitalopram and norsertraline metabolite formation were 5.3- and 1.7-fold
higher in induced fish than in the not induced S9 fraction, while the formation of metoprolol acid was
reduced by 3.4-fold. Sheep metabolic activity was evidently higher than in fish induced with BNF.
Table 2. Concentrations of metabolites formed under the tested conditions.
Metabolites Concentration, pmol/min/mg
LOQ 1
Min-Max, pmol/minControl
(without S9) Sheep S9 Fish S9 BNF
1 Fish S9
N-desmethylcitalopram <LOQ 2309 295 1557 8–23
Metoprolol acid <LOQ 443 274 81 11–27
Norsertraline <LOQ 3251 405 684 68–217
O-desmethylvenlafaxine <LOQ 823 <LOQ <LOQ 10–24
1 LOQ — limit of quantification; BNF — β-naphtaflavone.
2.3. N-desmethylcitalopram Formation
The kinetics of metabolite formation was assessed only for the citalopram compound,
since the formation of metoprolol acid and norsertraline was not non-linear within applied
substrate concentrations.
The kinetics of N-desmethylcitalopram was best described by the Michaelis–Menten equation
(r2 = 0.997; Figure 1). The maximum reaction speed (Vmax) and Michaelis constant (Km)
of N-desmethylcitalopram formation estimated from fitting to Michaelis-Menten equation were
1781 ± 90 pmol/min/mg and 29.7 ± 4.6 µM, respectively.
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Figure 1. Saturation curve for N-desmethylcitalopram formation from citalopram in S9 fractions from 
the liver of common carp (n = 12 in 3 pools with equal sex ratio). The dashed line indicates a 95% 
confidence level of the best-fit curve. 
2.4. Inhibition Study 
The rates of N-desmethylcitalopram formation from citalopram (5 μM) in the presence of 
inhibitor ellipticine (data not shown) show that 0.125 μM ellipticine reduced N-desmethylcitalopram 
formation by 30 ± 10%, while 1.25 and 12.5 μM completely inhibited N-desmethylcitalopram 
formation in the S9 fraction from common carp. 
3. Discussion 
Selected pharmaceuticals are widely prescribed in European countries [29,30] and have been 
routinely reported in different sample matrices, like sediment, sludge, soil, plants, and fish. Eighteen 
pharmaceuticals and seven metabolites have been identified in water and sediments from the pond, 
which receives discharged water from the WWTP of Vodňany town [20]. Fish living in that pond 
show the presence of 14 pharmaceuticals, including four parent compounds and their main 
metabolites (N-desmethylcitalopram, norsertraline, metoprolol acid, and O-desmethylvenlafaxine) 
in hepatic tissues [19,20]. However, it is not known whether these metabolites were taken up from 
the surrounding aquatic environment or produced by fish from the original compounds. To the best 
of our knowledge, this is the first study to report that hepatic S9 fractions of common carp were able 
to produce N-desmethylcitalopram, norsertraline, and metoprolol acid metabolites from citalopram, 
sertraline, and metoprolol, respectively. The use of a specific inhibitor of CYP1A suggested that 
CYP1A is involved in phase I biotransformation of citalopram in fish. 
In the present study, metoprolol, sertraline, and citalopram showed metabolite formation by the 
common carp hepatic S9 fraction. It is well-documented that these pharmaceuticals are metabolized 
in mammals by CYPs. For example, formation of desmethylcitalopram is catalyzed by the isoenzymes 
CYP2C19, CYP3A4, and CYP2D6 [31,32], formation of metoprolol acid by CYP2D6 [33] and 
norsertraline formation with CYP2C9, CYP3A4, CYP2C19, CYP2D6, and CYP2B6 [34–36] in 
mammals. To date, results from the studies on pharmaceutical compounds metabolism in fish (both 
in vivo and in vitro) remain controversial. It was suggested that after chronic exposure of diltiazem 
to rainbow trout, diltiazem metabolites had been identified in hepatic tissues of rainbow trout [18], 
contrary to Connors et al. [37], who could not find any diltiazem substrate depletion by the rainbow 
trout liver S9 fraction. 
The contribution of piscine CYPs to biotransformation of pharmaceuticals is less described 
compared to in mammalians. It is likely that some differences exist. Thus, venlafaxine is attributed 
by CYP2D6, CYP2C19, and CYP3A4 in humans [38]. Fish S9 fractions are lacking activity toward the 
prototypical human CYP2C substrates [23]. Earlier, it was shown that venlafaxine did not alter 
CYP1A and CYP3A-like mediated reactions, such as ethoxyresorufin-O-deethylase (EROD) and 
benzyloxy-4-trifluoromethylcoumarin-O-debenzyloxylase (BFCOD) activity in the rainbow trout 
microsomal fraction [39]. Based on these results, we could not find the main venlafaxine metabolite 
Figure 1. Saturation curve for N-desmethylcitalopram formation from citalopram in S9 fractions from
the liver of common carp (n = 12 in 3 pools with equal sex ratio). The dashed line indicates a 95%
confidence level of the best-fit curve.
2.4. Inhibition Study
The rates of N-desmethylcitalopram formation from citalopram (5 µM) in the presence of inhibitor
ellipticine (data not shown) show that 0.125 µM ellipticine reduced N-desmethylcitalopram formati n
by 30 ± 10%, whil 1.25 a d 12.5 µM completely inhibited N-desm thylcitalopram formation in the S9
fraction from common carp.
3. Discussion
Selected pharmaceuticals are widely prescribed in European countries [29,30] and have been
routinely reported in different sample matrices, like sediment, sludge, soil, plants, and fish. Eighteen
pharmaceuticals and seven metabolites have been identified in water and sediments from the pond,
which receives discharged water from the WWTP of Vodnˇany town [20]. Fish living in that pond show
the presence of 14 pharmaceuticals, including four parent compounds and their main metabolites
(N-desmethylcitalopram, norsertraline, metoprolol acid, and O-desmethylvenlafaxine) in hepatic
tissues [19,20]. However, it is not known whether these metabolites were taken up from the surrounding
aquatic environment or produced by fish from the original compounds. To the best of our knowledge,
this is the first study to report that hepatic S9 fractions of common carp were able to produce
N-desmethylcitalopram, norsertraline, and metoprolol acid metabolites from citalopram, sertraline,
and metoprolol, respectively. The use of a specific inhibitor of CYP1A suggested that CYP1A is
involved in phase I biotransformation of citalopram in fish.
In the present study, metoprolol, sertraline, and citalopram showed metabolite formation by the
common carp hepatic S9 fraction. It is well-documented that these pharmaceuticals are metabolized in
mammals by CYPs. For example, formation of desmethylcitalopram is catalyzed by the isoenzymes
CYP2C19, CYP3A4, and CYP2D6 [31,32], formation of metoprolol acid by CYP2D6 [33] and norsertraline
formation with CYP2C9, CYP3A4, CYP2C19, CYP2D6, and CYP2B6 [34–36] in mammals. To date,
results from the studies on pharmaceutical compounds metabolism in fish (both in vivo and in vitro)
remain controversial. It was suggested that after chronic exposure of diltiazem to rainbow trout,
diltiazem metabolites had been identified in hepatic tissues of rainbow trout [18], contrary to Connors
et al. [37], who could not find any diltiazem substrate depletion by the rainbow trout liver S9 fraction.
The contribution of piscine CYPs to biotransformation of pharmaceuticals is less described
compared to in mammalians. It is likely that some differences exist. Thus, venlafaxine is attributed
by CYP2D6, CYP2C19, and CYP3A4 in humans [38]. Fish S9 fractions are lacking activity toward
the prototypical human CYP2C substrates [23]. Earlier, it was shown that venlafaxine did not
alter CYP1A and CYP3A-like mediated reactions, such as ethoxyresorufin-O-deethylase (EROD)
and benzyloxy-4-trifluoromethylcoumarin-O-debenzyloxylase (BFCOD) activity in the rainbow trout
microsomal fraction [39]. Based on these results, we could not find the main venlafaxine metabolite
by carp S9. Therefore, venlafaxine and its metabolite, which were found in fish tissue from the
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pond system, were removed from the water. Venlafaxine and O-desmethylvenlafaxine could be
bioavailable in the fish circulation system and provoke adverse effects, which is connected with changes
in behavioral performance [40].
Citalopram is a selective serotonin reuptake inhibitor medication and is one of the most
prescribed and used antidepressants in the world [41], due to its low potential to show clinically
relevant drug-drug interactions, lower binding affinity to serum proteins, and low cardiac toxicity
compared to other antidepressants [42–44]. Citalopram and its metabolite N-desmethylcitalopram
were found in different environmental matrices (water, sediment, and fish) of the pond which
received discharged water from WWTP of Vodnˇany town [20]. The average concentration of
citalopram and N-desmethylcitalopram found in all analyzed hepatic tissue of common carp
was 3.1 ± 2.9, and 2.6 ± 1.4 ng/g wet weight, respectively [19]. The major metabolic pathway of
citalopram was previously described by von Moltke et al. [45], where biphasic plots for citalopram
N-demethylation with Vmax 25 and 158 pmol/min/mg and Km 17.3 and 184.9 µM for at least two
enzymes, respectively, was shown using human hepatic microsomes. However, when data were
placed on the monophasic model, Vmax reached 183–281 pmol/min/mg for N-desmethylcitalopram.
Further formation of N-desmethylcitalopram indicated that CYP3A4, 2C19, and 2D6 contribute
N-demethylation of citalopram [45]. In the present study, Michaelis-Menten parameters of formation of
N-desmethylcitalopram by the fish hepatic S9 fraction were 1781 pmol/min/mg Km 29.7 µM. The further
involvement of CYP1A1 enzymes in the metabolism of citalopram was investigated using the selective
chemical inhibitor ellipticine. Our inhibition study showed that ellipticine decreased the formation of
N-desmethylcitalopram, suggesting that CYP1A protein is involved in citalopram metabolism in fish.
Fish CYP1A is the most studied xenobiotic-metabolizing enzyme in phase I due to its toxicological
importance. This enzyme can be induced or inhibited by several xenobiotics [46], altering the toxicity
of chemical contaminants. BNF is a well-known agonist of the aryl hydrocarbon receptor, which results
in an increase of transcription of CYP1A and CYP1A enzyme activity. Since the exposure of fish to
environmental contaminants can result in the induction of CYP1A, thus, different outcomes might arise
for pharmaceuticals metabolized typically or mainly by this isoform. In the present study, we tested
whether fish, induced with BNF, can show different patterns of metabolite formation due to the
interaction of parent pharmaceutical compounds and elevated CYP1A1. The N-desmethylcitalopram,
norsertraline, and metoprolol acid metabolite formation differed in the S9 fraction from common carp
induced with BNF. A concentration greater than 5-times concentration that of N-desmethylcitalopram
was formed by S9 fraction from BNF induced fish, suggesting synergistic or additive effect.
This study contributes to the current knowledge on pharmaceutical bioaccumulation and
pharmacokinetics. In summary, fish can generate the main metabolites of metoprolol, sertraline,
and citalopram during hepatic metabolism. The inhibition data indicated that the co-administration
of citalopram with other pharmaceuticals from water might suggest inhibition of at least the piscine
CYP1A1. To evaluate the potential adverse effects in aquatic organisms, further studies are now needed
that combine pharmaceuticals with different pharmacological effects. Furthermore, role of phase II
metabolic reactions should be explored.
4. Materials and Methods
4.1. Chemicals and Reagents
Chemicals were purchased from multiple companies at the highest available purity.
Citalopram, sertraline, and venlafaxine were purchased from AK Scientific (Union City, NJ,
USA); metoprolol and tris(n-butyl) phosphate (TNBP) from Sigma Aldrich (Darmstadt, Germany);
metabolites norsertraline and N-desmethylcitalopram from Labicom (Olomouc, The Czech Republic);
metoprolol acid from Toronto Research Chemicals and O-desmethylvenlafaxine; and chemicals
for preparation of S9 fractions and performing biochemical reactions from Sigma Aldrich
(Darmstadt, Germany). An analytical procedure was performed using internal standards
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(IS). An isotope-labelled carbamazepine (D10) was obtained from CDN Isotopes (Pointe-Claire,
QC, Canada), citalopram (D6), venlafaxine (D6) and sertraline (D3) were purchased from
Lipomed AG (Arlesheim, Switzerland), and metoprolol (D7) was obtained from Alsachim
(Strasbourg, France). Chemical reaction compartments nicotinamide-adenine dinucleotide
phosphate (NADPH), uridine 5′- diphosphoglucuronic acid (UDPGA), resorufin, 7-ethoxyresorufin,
7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-hydroxy-4-trifluoromethylcoumarin (HFC) and
ellipticine were purchased from Sigma Aldrich (Darmstadt, Germany). Organic solvents for HPLC-MS
(LC-MS grade) were purchased from Merck (Darmstadt, Germany). Citalopram, metoprolol, sertraline,
and venlafaxine stocks for the experiment were prepared at concentrations of 20 mM in methanol and
stored at −20 ◦C until use.
4.2. Animals
Fish. Fish were collected from a fishpond with a low concentration level of pharmaceuticals
(305–880 ng/POCIS) [10]. Thus, fish were stocked in the pond for 1 year with a natural photoperiod.
The fish were allowed to eat and swim freely in the pond without interaction with humans and
avoiding stress conditions. In total, 1-year-old common carps (n = 12) weighing 695 ± 116 g (mean
± standard deviation) and length 330 ± 19 mm were collected during spring 2018. Additionally,
β-naphtaflavone (BNF) was administrated into four fish at levels of 50 mg/kg of BNF in corn oil.
Following administration, individuals were kept in a separate aquaria for 48 h, in order to achieve
CYP1A1 induction. The fish were then sacrificed according to the ethical rules of the EU harmonized
Animal Welfare Act of the Czech Republic. The unit is licensed (No. 53100/2013-MZE-17214), according
to the Czech National Directive (the Law against Animal Cruelty, No. 246/1992). Before sampling,
fish were anesthetized in an ice bath, and their spinal cords were immediately cut. Fish was bloodless
and hepatic tissues were collected and stored at −80 ◦C before use for the preparation of S9 fraction.
Sheep. Hepatic tissue from one male and one female Suffolk sheep (age, 2 years; weight 70–80 kg)
were collected at a slaughterhouse in Vodnˇany town, Czech Republic, and stored at −80 ◦C. Sheep is
a relatively new animal model, which has started to be used in veterinarian investigations related
to drug-drug interactions, as well as for effective therapy and the limitation of drug-resistance
development. Sheep phase I biotransformation enzymes, including CYPs-dependent metabolic
activities in sheep liver, were already characterized by Szotakova et al. [47], Maté et al. [48] and
Stuchlíková et al. [49]. The use of the S9 fraction from sheep hepatic tissue could represent the
mammalian metabolic system in relation to selected pharmaceuticals.
4.3. Preparation of S9 Fraction
Hepatic tissue (approx. 1.2 g) of twelve individual common carps and two individual sheep
were homogenized in 10 mM Tris–HCl buffer, pH 7.4, containing 250 mM sucrose separately using
an T-25 Ultra Turrax homogenizer Ika (Staufen, Germany) followed by centrifugation at 10,000× g
for 15 min at 4 ◦C to obtain S9 fractions. The protein concentration in S9 fractions was determined
by the colorimetric method according to Smith et al. [50] at 595 nm. The S9 fractions were diluted to
10 mg/mL protein content. To account for the gender effect, four piscine S9 fractions were combined in
one pool with the same ratio of males/females (1:1). The incubations were performed using three S9
pools from common carp. One pool was prepared from ovine S9 fractions.
4.4. S9 Fraction Characterization
The EROD and BFCOD activity were measured using black 96-well plate [51]. Individual standard
curves of resorufin and HFC were used to calculate amount of product, which was produced in one
minute by one mg of protein. The EROD incubation mixtures consisting of 0.2 mg of protein, 2 µM
of 7-ethoxyresorufin, incubation medium (50 mM potassium phosphate buffer, pH 7.4), and 1 mM
NADPH. The BFCOD incubation mixtures consisting of 0.2 mg of protein, 150 µM of BFC, incubation
Molecules 2020, 25, 2690 7 of 11
medium (50 mM potassium phosphate buffer, pH 7.4), and 0.5 mM NADPH. The total reaction volume
was 260 mL in each well.
4.5. In Vitro Incubation of S9 Fraction with Pharmaceutical Compounds
In this in vitro study, applied concentration of pharmaceutical compounds was 1000 times higher
than the concentration detected in common carp liver (0.4–3 ng/g) and blood plasma (0.13–0.24 ng/g)
from in situ experiment in Cezarka pond [19].
To investigate the formation of metabolites, one concentration of pharmaceutical (2 µM) was
incubated with 1 mg of protein in piscine or ovine S9 fraction, 1 mM NADPH, and 0.3 mM UDPGA in a
potassium phosphate buffer (50 mM, 7.4 pH) (Table 2). The total volume of each incubation was 0.5 mL.
The incubation mixture was vortexed and incubated for 1 h in a water bath (at 21 ◦C for fish and 37 ◦C
for ovine). Then, the reaction was stopped by the addition of 0.5 mL ice-cold methanol, vortexed, and
centrifuged at 10,000× g for 10 min. Four types of control incubation with no substrate or with no S9
protein fractions were also prepared to confirm the absence of interfering compounds and to identify
any non-metabolically formed compounds. Sheep hepatic S9 fraction was used as a positive control,
because sheep S9 fractions are known to metabolise the studied compounds. Additionally, control
incubations (Table 3), with active and heat inactivated piscine and ovine S9 fractions, were conducted.
The supernatant was filtrated (0.45 µm regenerated cellulose filter) and the internal standard for
chemical analyses was added. According to Hou et al. [52], Carassius carassius hepatic microsomes can
metabolize TNBP in vitro. Therefore, in this study, TNBP was selected as a compound to confirm the
ability of common carp S9 fractions to form metabolites. S9 fractions with TNBP were incubated under
the same conditions as other pharmaceuticals. The choice of optimal conditions for incubations with
regards to the linearity of incubation time and protein concentrations was based on a previous study at
our laboratory [24]. The kinetics of metabolite formation was continued only with a compound that
shows the linear range for the rate of metabolite formation by fish S9 fractions.
Table 3. Incubation procedure of piscine or ovine S9 fractions to study formation of major metabolites
of selected pharmaceuticals.
Incubation
Type Buffer Pharmaceutical S9 fraction Co-Factors Pharmaceutical Concentration
Control + - + piscine or ovine + -
Control + - + piscine or ovine + -
Control + - + piscine or ovine + -
Control + + - + 2 µM of citalopram or
metoprolol or TNBP or
sertraline or venlafaxine
Test + + + piscine or ovine +
“+”—indicator of added compound to incubation; “-“—indicator of absence compound in incubation;
TNBP—tris(n-butyl) phosphate.
4.6. The Kinetic Study Focused on Citalopram
Kinetic analysis using multiple substrate concentrations was conducted only with citalopram
using the same procedure as above-described. The substrate concentrations were 0.01, 0.03, 0.1, 1, 10,
50, 75, and 100 µM of citalopram.
4.7. Inhibition Study Focused on Citalopram
Ellipticine (a specific inhibitor of mammalian [53] and piscine [54] CYP1A1) was used to investigate
if CYP1A1 was responsible for metabolite formation. Incubations were performed only with citalopram.
Three concentrations of ellipticine were used in the final incubations: 0.125, 1.25, and 12.5µM. The choice
of these concentrations was based on the previous results [25]. The degree of inhibition was assessed by
comparison of metabolite formation in the presence and absence of inhibitor. The incubation without
inhibitor contained the same amount of methanol as in the incubations with inhibitor (0.5% from total
incubation volume).
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4.8. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS)
The concentrations of the parent compound and its main metabolites (metoprolol acid,
N-desmethylcitalopram, norsertraline, and O-desmethylvenlafaxine) were determined by LC HRMS
(Thermo Fisher Scientific, San Jose, CA, USA). The chromatographic separation was performed on a
Hypersil Gold aQ analytical column (50 × 2.1 mm; 5 µm particles, Thermo Fisher Scientific). The mobile
phase consisted of solvent A (water acidified with 0.1% formic acid) and solvent B (acetonitrile with
0.1% formic acid). The gradient was set as follows: 0–1 min 100% A, 1–4 min decrease to 75% A,
with 350 µL/min flow rate; then 4–8 min 40% A, 8–10 min 0% A, 10–12 min 0% A with 450 µL/min
flow rate; then 12.05–15 min 100% A with 350 µL/min flow rate. A heated electrospray ionization
(HESI) source was used for the ionization of the target compounds with a spray voltage of 3.5 kV
and nitrogen as the sheath gas (40 arbitrary units), auxiliary gas (10 arbitrary units), and collision gas.
The full scan mode with high resolution (70000 FWHM) in range 100–750 m/z was used with the AGC
target 3e6, and the maximum filling time 50 ms. Data acquisition was performed with Xcalibur 4.3
Software, and data processing was performed using TraceFinder 3.3 Software (both Thermo Fisher
Scientific, San Jose, CA, USA). Internal standard and matrix matching standard methods were used for
the quantification of target analytes.
4.9. Data Analysis
The data were analyzed using non-linear regression analysis (GraphPad Prism version 4.0 for
Windows, GraphPad Software, San Diego, CA, USA). The data were fitted to the Michaelis-Menten
equation and two enzyme models. The goodness of fit was assessed by comparison of the coefficient
of determination (r2). Visual analysis of Eadie-Hofstee plots was used to estimate whether one or more
enzymes participate in the reaction.
Supplementary Materials: The supplementary material 1 is available online at https://zenodo.org/deposit/3833659.
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